Opexa Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants

Opexa Therapeutics, Inc. OPXA, a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that is offering to sell shares of its common stock and common stock purchase warrants in an underwritten public offering. All of the shares in the offering are to be sold by Opexa. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.